Pittenger & Anderson Inc. Has $7.59 Million Position in Zoetis Inc. $ZTS

Key Points

• Pittenger & Anderson cut its Zoetis stake by 30.2% in Q4 to 60,290 shares worth $7.59 million, while institutional investors own about 92.8% of the stock (Vanguard holds ~47.8 million shares valued at $6.01 billion).
• Analysts have a consensus rating of Hold with an average target of $151.75 (mixed coverage: 7 Buy, 7 Hold, 1 Sell) and several firms recently trimmed price targets, signaling tempered expectations.
• Zoetis recently beat Q results (EPS $1.48 vs $1.40), set FY2026 guidance of 7.00–7.10 EPS, pays a $0.53 quarterly dividend (annual $2.12, ~1.9% yield), and trades around $114 with a 52-week high of $172.23.

Pittenger & Anderson Inc. reduced its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 30.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 60,290 shares of the company's stock after selling 26,124 shares during the period. Pittenger & Anderson Inc.'s holdings in Zoetis were worth $7,586,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Vanguard Group Inc. increased its stake in Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company's stock valued at $6,011,802,000 after buying an additional 5,474,210 shares during the last quarter. Diamond Hill Capital Management Inc. acquired a new position in Zoetis in the 3rd quarter valued at about $394,010,000. Nordea Investment Management AB grew its stake in Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock valued at $622,222,000 after buying an additional 2,179,578 shares during the last quarter. Montrusco Bolton Investments Inc. grew its stake in Zoetis by 256.7% in the 4th quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company's stock valued at $266,888,000 after buying an additional 1,560,314 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in Zoetis by 83.4% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company's stock valued at $394,746,000 after buying an additional 1,227,085 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Piper Sandler reissued a "neutral" rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Leerink Partners reissued a "market perform" rating on shares of Zoetis in a research note on Tuesday, March 10th. UBS Group lowered their target price on shares of Zoetis from $136.00 to $130.00 and set a "neutral" rating for the company in a research note on Tuesday, April 28th. Citigroup started coverage on shares of Zoetis in a report on Wednesday, April 15th. They set a "buy" rating and a $145.00 price objective for the company. Finally, Bank of America lifted their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a "neutral" rating in a report on Friday, February 13th. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $151.75.

Zoetis Price Performance

Shares of Zoetis stock opened at $114.22 on Friday. Zoetis Inc. has a 52-week low of $112.97 and a 52-week high of $172.23. The stock has a market capitalization of $48.05 billion, a price-to-earnings ratio of 18.97, a price-to-earnings-growth ratio of 1.76 and a beta of 0.87. The company has a fifty day moving average of $119.93 and a 200-day moving average of $124.67. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion during the quarter, compared to analysts' expectations of $2.36 billion. During the same quarter in the prior year, the company earned $1.40 EPS. The firm's revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts expect that Zoetis Inc. will post 7.01 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.9%. Zoetis's dividend payout ratio is 35.22%.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.